Exane Asset Management acquired a new stake in shares of Celgene Co. (NASDAQ:CELG) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,656 shares of the biopharmaceutical company’s stock, valued at approximately $211,000.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Ayalon Holdings Ltd. purchased a new stake in Celgene in the second quarter valued at $100,000. Atlantic Trust LLC purchased a new stake in Celgene in the second quarter valued at $101,000. Acropolis Investment Management LLC purchased a new stake in Celgene in the second quarter valued at $112,000. Moneta Group Investment Advisors LLC boosted its holdings in Celgene by 2,688.6% in the second quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 9,921 shares during the last quarter. Finally, Archford Capital Strategies LLC purchased a new stake in Celgene in the first quarter valued at $124,000. 73.11% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Ernest Mario sold 12,000 shares of the company’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $92.32, for a total transaction of $1,107,840.00. Following the completion of the transaction, the director now owns 44,413 shares in the company, valued at approximately $4,100,208.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director John H. Weiland purchased 5,575 shares of Celgene stock in a transaction that occurred on Tuesday, August 7th. The shares were bought at an average price of $89.73 per share, with a total value of $500,244.75. The disclosure for this purchase can be found here. 0.39% of the stock is owned by corporate insiders.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.05. Celgene had a net margin of 19.81% and a return on equity of 87.28%. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.70 billion. During the same quarter in the prior year, the firm earned $1.82 EPS. The company’s revenue for the quarter was up 16.6% on a year-over-year basis. As a group, sell-side analysts expect that Celgene Co. will post 7.64 earnings per share for the current year.
Several equities research analysts have commented on CELG shares. Mizuho reaffirmed a “buy” rating and issued a $118.00 price target on shares of Celgene in a report on Tuesday, July 10th. Zacks Investment Research lowered shares of Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, July 18th. BidaskClub raised shares of Celgene from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. Morgan Stanley upped their price target on shares of Celgene from $91.00 to $93.00 and gave the company an “equal weight” rating in a report on Friday, July 27th. Finally, Cowen reaffirmed a “buy” rating and issued a $150.00 price target on shares of Celgene in a report on Tuesday, July 10th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $121.42.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.